Q-omics provides the consensus-scored FOLH1B profile across patient tissues and cancer cell-line models. FOLH1B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FOLH1B is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, FOLH1B RNA expression shows 7,680 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KIRP, and THYM as cancer lineages where FOLH1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOLH1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOLH1B survival associations across molecular data types. FOLH1B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOLH1B RNA expression–survival associations across cancer types. High FOLH1B expression shows unfavorable associations in STAD, THYM and COAD, but favorable associations in KIRC, UCEC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FOLH1B RNA expression.
This table summarizes FOLH1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for FOLH1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOLH1B shows lower tumor expression in KIRP, KIRC, LIHC, KICH and CHOL and higher tumor expression in PRAD. The KIRP box plot shows higher FOLH1B RNA expression in normal versus tumor tissue (log2 FC = −2.377, t-test p < 0.001).
This table shows molecular features associated with FOLH1B in patient tissues and cancer cell lines. In patient samples, FOLH1B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOLH1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS.
